webinar register page

Webinar banner
Accenture: The Promise of Decentralized Clinical Trials
Join us for a discussion on the opportunities and value that a decentralized clinical trial approach offers patients and stakeholders, as well as the challenges that sponsors can face in working to create these new experiences. Additionally, we will be looking at where the ecosystem of CROs, Sponsors, and Device vendors are heading and how they are looking to better support new modalities and drive adoption moving forward.

Presented by Sam Bavery, senior manager at Accenture Life Science, and Paul O'Malley, management consultant manager at Accenture Life Science.

Note: **This event requires advance registration and is exclusively for Exchange members and Mayo Clinic employees, residents and students.**

Aug 10, 2021 05:00 PM in Eastern Time (US and Canada)

Webinar logo
* Required information


Samuel Bavery
Senior Manager @Accenture
Sam’s career has been focused on patient centric design in the healthcare ecosystem. He began his career focused on patient centric design with payors and providers. Working to create disease management programs, facilitate the sharing of patient health records digitally, and report value based care metrics. He has used that experience in the Clinical Development space to start to think about how we can re-design clinical trials with a focus on patient support and the use of real world data. Currently he is focused on driving adoption of the use of digital tools in clinical trials, and the transition to decentralized trials to provide better access for patients and more efficient operations for sponsors.
Paul O'Malley
Management Consultant Manager @Accenture
Paul is a management consultant within Accenture’s Life Sciences practice dedicated to the Research and Development (R&D) domain. He has a diverse background in strategic planning, technology assessments, and value management within clinical research. Currently, Paul is focused on the disruption of traditional clinical trial methodologies to provide cycle-time reductions and the improvement of in-trial experience for both patients and site partners. Lastly, Paul is keen on understanding the current clinical trial ecosystem limitations of legacy processes, technology barriers, and stakeholders' impact that ultimately inhibit the industry's transition to decentralized trials.